BLUE bluebird bio, Inc.

Price (delayed)

$44.01

Market cap

$2.92B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.98

Enterprise value

$2.79B

Sector: Healthcare
Industry: Biotechnology
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Highlights

The EPS has increased by 16% year-on-year and by 7% since the previous quarter
The company's net income rose by 10% YoY
The quick ratio has contracted by 20% from the previous quarter but it has grown by 4.9% YoY
bluebird bio's equity has decreased by 9% from the previous quarter but it has increased by 3.5% YoY

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
66.37M
Market cap
$2.92B
Enterprise value
$2.79B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
11.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.17
Earnings
Revenue
$250.02M
EBIT
-$658.65M
EBITDA
-$639.21M
Free cash flow
-$507.62M
Per share
EPS
-$10.98
Free cash flow per share
-$7.66
Book value per share
$23
Revenue per share
$3.77
TBVPS
$29
Balance sheet
Total assets
$1.95B
Total liabilities
$422.46M
Debt
$195.29M
Equity
$1.52B
Working capital
$1.1B
Liquidity
Debt to equity
0.13
Current ratio
6.57
Quick ratio
6.39
Net debt/EBITDA
0.2
Margins
EBITDA margin
-255.7%
Gross margin
98%
Net margin
-256.8%
Operating margin
-261.5%
Efficiency
Return on assets
-35.1%
Return on equity
-45.8%
Return on invested capital
-52.8%
Return on capital employed
-37.7%
Return on sales
-263.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
-0.11%
1 week
3%
1 month
-14.89%
1 year
-45.63%
YTD
-49.85%
QTD
-18.42%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$250.02M
Gross profit
$245.05M
Operating income
-$653.75M
Net income
-$642.17M
Gross margin
98%
Net margin
-256.8%
BLUE's operating margin has surged by 81% year-on-year and by 7% since the previous quarter
bluebird bio's net margin has soared by 81% YoY and by 6% from the previous quarter
bluebird bio's operating income has increased by 11% YoY and by 2.8% from the previous quarter
The company's net income rose by 10% YoY

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
1.91
P/S
11.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.17
The EPS has increased by 16% year-on-year and by 7% since the previous quarter
BLUE's P/B is 47% below its 5-year quarterly average of 3.6 and 27% below its last 4 quarters average of 2.6
bluebird bio's equity has decreased by 9% from the previous quarter but it has increased by 3.5% YoY
BLUE's P/S is 93% below its 5-year quarterly average of 178.1 and 75% below its last 4 quarters average of 46.3
The revenue is up by 4.3% since the previous quarter

Efficiency

How efficient is bluebird bio business performance
The return on sales has surged by 81% year-on-year and by 7% since the previous quarter
bluebird bio's return on invested capital has decreased by 24% YoY but it has increased by 3.3% QoQ
bluebird bio's ROE has decreased by 8% YoY but it has increased by 2.6% from the previous quarter
bluebird bio's ROA has increased by 2.5% from the previous quarter

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The quick ratio has contracted by 20% from the previous quarter but it has grown by 4.9% YoY
The current ratio has contracted by 20% from the previous quarter but it has grown by 6% YoY
bluebird bio's debt is 87% less than its equity
bluebird bio's equity has decreased by 9% from the previous quarter but it has increased by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.